Abstract. Breast cancer is the most frequently diagnosed female cancer all over the world. Although the molecular genetics of this disease has been the focus of many projects for over 20 years, the number of prognostic markers used in clinics is still unsatisfactory. Mitochondrial DNA mutations have been reported in many breast cancer studies. To investigate the possible role of mitochondrial inherited polymorphisms in breast cancer development we analyzed the sequence of NADH-dehydrogenase genes in cancer samples and their corresponding normal tissues. We detected increased incidence of mtDNA polymorphisms, in particular very rare polymorphisms such as A4727G, G9947A, A10044G, A10283G, T11233C, and C11503T. Our report supports the notion that mtDNA polymorphisms establish a specific genetic background for breast cancer development and that mtDNA analysis may help in selection of cohorts that should undergo intensive screening and early detection programs.
Introduction
An estimated 1,152,161 new breast cancer (BC) cases are diagnosed worldwide per year (1) . Although much effort has been made, molecular studies of breast cancer pathology and etiology have so far failed to identify successful primary prevention strategies. The reduction of mortality from BC is now only possible thanks to early detection that must become the highest priority. The reduction of death rate from BC may result from increased mammography/sonography screening programs and subsequent detection of the disease at an early stage. Biomarkers and tests that indicate additional risk could help in the selection of populations at higher risk and should be used in BC (2) . Today it seems possible that a molecular mtDNA-analysis-based approach may fulfill at least some of the BC biomarker requirements.
This interest in mitochondrial function in carcinogenesis was reported as early as in the 1920s, when Otto Warburg discovered that cancer cells have a high glycolytic rate and produce increased levels of lactate in the presence of oxygen. This discovery has opened a new field of research currently referred to as 'mitochondrial medicine' and 'mitochondrial oncology'. Multiple reports have found an association between somatic mtDNA mutations and cancer development, progression or metastasis and inherited mtDNA polymorphisms have been indicated as contributing factors in cancer development (3) (4) (5) .
For the last few years in parallel to nuclear genome research, mtDNA has also been screened for mutations specific for breast cancer. Breast nipple aspirate fluid with mtDNA mutations at positions 204, 207 and 16293 has been suggested as an indicative for breast cancer (6) and mtDNA D-loop mutations have been proposed as independent prognostic marker in breast cancer (7) . We have shown that individuals who inherited the A10298G polymorphism are at higher risk for developing BC (8) . As A10398G is located in the ND3 (NADHd-dehydrogenase subunit 3) we have been interested if any other polymorphisms are abundant in ND genes in the BC cohort. Our interest was further increased as human mammary carcinoma cells were shown to have depressed expression levels of complex I (CI, NADH-ubiquinone oxidoreductase) genes (9) . Also in prostate cancer ND6 transcript levels are significantly decreased in tumor samples when compared to their paired normal tissue (10) . CI gene expression is also reduced in glioblastoma (11) and in photodynamic therapy-resistant colon carcinoma cells (12) . At the same time benign renal oncocytomas were shown to be deficient in electron transport chain complex I proteins and to harbor point mutations in CI genes (13) . Moreover, the HPLC study of ND4 mutations in transitional cell carcinomas has proven that most mito-chondrial mutations identified in tumors pre-exist in the heteroplasmic state in a minority of mtDNA molecules in the cell. These are too low in quantity to be detected by methods such as DNA sequencing. The authors suggested that mtDNA mutations occur before tumorigenesis and become apparent in cancer cells (14) . Gasparre et al hypothesised that the clonal amplification of mtDNA with mutated CI genes in tumors demonstrates that these alterations are selected and therefore favor or trigger growth (13) . In light of these data we believe that specific inherited mtDNA variants may influence the cancer development susceptibility of an individual in addition to nuclear DNA and environmental factors. In our opinion, such mitochondrial abnormalities as NADHubiquinone oxidoreductase polymorphisms may play a role in modifying an individual's risk to breast cancer (15) and should be included in the diagnostic algorithm for identification of individuals with hereditary predisposition to breast cancer along with BRCA pathway mutations and clinical parameters (16) . In the present study, we examined the genetic alterations in the NADH-dehydrogenase region of mtDNA in primary human BCs and their paired control samples.
Materials and methods
Patients. The population of patients originated from our previous study (8 Table I .
Fifty-microlitre reactions contained 10 ng DNA and 0.5 μM primers, 0.2 mM each of deoxynucleotide triphosphate (dNTP), 1 U of AmpliTaq Gold ® DNA Polymerase and 2.5 mM MgCl 2 . DNA was subjected to the following cycling conditions: initial denaturing at 95˚C for 3 min followed by 94˚C for 1 min, 55˚C for 30 sec, and 72˚C for 1 min for 40 cycles and final extension step at 72˚C for 7 min. Two microlitres of PCR products was analysed on an ethidium bromide-stained, 3% agarose gel (40 min at 70 V) to demonstrate the presence of the amplification product and for its quantification. 
Results
Breast cancer population of patients is characterized by 28 germ-line polymorphisms (Table II) that differentiate BC patients from haplogroup H (18, 19) , the most common haplogroup in Poland, and the haplogroup we have shown to be at lower risk for BC development. In particular, 68% (19) of discovered polymorphisms were very rare (20) , while polymorphism T5082C has not been reported before (21) . We have classified polymorphisms including A4727G, A4745G, T5082C, G9947A, A10044G, A10283G, T11233C, C11503T, A13722G as very rare. These have been reported before in <20 cases (20) . The majority of polymorphisms described by us are synonymous and only four -G5046A, G5460A, G8557A and G13759A-polymorphisms change the amino acid sequence of the protein. Comparing cancer tissue and normal breast (control) tissue, we did not detect any somatic mtDNA mutations, point mutations, insertions or deletions.
Discussion
A number of studies have proven that mitochondrial DNA mutations are more powerful in detecting tumor cells in bodily fluids and cytological specimens than mutations in nuclear DNA (5) and we believe this can be applied to BC screening. Thus, we suggest that analysis of mtDNA polymorphisms and possibly also mutations may be useful to select a population at increased risk of cancer development. Table I . Primers used for sequencing mitochondrial NADHdehydrogenase genes. Table II . Germ-line polymorphisms in the NADH-dehydrogenase mtDNA of the breast cancer patients. 
-------------------------------------------------CRS no. 5'-primer-3' ------------------------------------------------

GTGTGTTGGTTAGTAGGCCT -------------------------------------------------
-----------------------------------------------------------------------------------------------------
Amino acid change Gene ----------------------------------------------------------------------------------------------------
Unless indicated otherwise, the data are from MITOMAP (32) and mtDB (20) databases and the references therein. Syn, synonymic mutation; NC, non coding region.
- ---------------------------------------------------------------------------------------------------- Cancer control efforts in the postgenomic era should be focused at both population and individual levels to develop novel risk assessment strategies that will reduce the morbidity and mortality associated with breast cancer. Mitochondrial polymorphisms described by us as specific in BC population have been shown before as good candidates for identification purposes in criminal and forensic medicine. It has been proven that T5004C may be used to resolve identity of people with otherwise identical mitotype and A5656G may be used even in the case of samples with highly degraded DNA (22) . Position 11719 in the MTND4 gene was described as a 'hot spot' for base substitutions and as a position suitable for identification purposes in Legal Medicine (23) . At the same time some of our BC-associated polymorphisms have been described before as typical for particular haplogroups. This further supports the hypothesis that some haplogroups are preferential candidates for cancer development and that haplogroup specific polymorphisms are sequence variation hot-spots. The abundance of polymorphisms such as A5656G and G11719A in cancer population seem to favour this hypothesis. In fact A5656G was associated exclusively with mtDNA haplogroup U (24) and G11719A is a marker of non-HV haplogroups (25) .
Few of the polymorphisms discovered by us have been analyzed before as disease-associated factors. In particular, 11719A is a marker of reduced sperm motility (25) and the allele A at 12308 in tRNA(Leu) was reported to increase the risk of oral cancer (26) . The transition A10044G in the tRNA(Gly) gene was associated with sudden unexpected death in a family with severe encephalopathy (27) . In addition, the missense mutation G5460A affecting the ND2 was reported in pathologically proven Parkinson and Alzheimer's diseases (28) . Therefore, it cannot be excluded that mtDNA polymorphisms may result in disturbed protein synthesis, synthesis rate or finally in changed protein structure and therefore influence mitochondrial and cell physiology with the consequence of cancer development susceptibility (3) (4) (5) 8, 29) .
In conclusion, we suggest that mitochondrial research will enable the establishment of biomarkers helping to identify individuals at high risk for developing specific cancer types and to develop screening approaches for early diagnosis of cancer. Molecular assessment of mitochondrial abnormalities of cancer cells could represent a promising tool for early diagnosis of neoplasia (30, 31) .
